Pharmafile Logo
Pharmafocus logo
Advanced Search

AstraZeneca

Showing 15 posts of 785 posts found.

4420456374_64a3d7e6aa

Top ten stories in the pharmaceutical industry this week

September 9, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ABPI, AstraZeneca, BMS, Celgene, Cloud Computing, Eisai, FDA, GSK, Halaven, Novartis, Novo Nordisk, Roche, Teva, agios, epipen, rheumatoid arthritis

It’s Friday, and that means it’s time for another run-down of the biggest stories on Pharmafile.com over the last week. …

News
astrazeneca_sign_sky

AZ’s first respiratory biologic meets primary endpoints in Phase III trials

September 5, 2016
Research and Development, Sales and Marketing AstraZeneca, asthma, benralizumab, biologic, respiratory, severe asthma

AstraZeneca has presented Phase III data at the European Respiratory Society (ERS) international congress which shows that trial biologic benralizumab …

News

AstraZeneca to pay £5.52 million to settle bribery probe

August 31, 2016
Research and Development AstraZeneca, SEC, misconduct

According to US regulators, AstraZeneca is to pay $5.52 million to resolve a foreign bribery probe investigating payments made to …

News
pfizer_sky

Pfizer to acquire AstraZeneca’s anti-infective business for $550 million upfront

August 24, 2016
Research and Development, Sales and Marketing AstraZeneca, Pfizer, Zavicefta, anti-infective

Pfizer has announced that it is to acquire AstraZeneca’s small molecule anti-infective business in a deal potentially worth up to …

News
astrazeneca_logo_building

FDA fast tracks Alzheimer’s drug from Lilly, AstraZeneca

August 22, 2016
Manufacturing and Production, Research and Development Alzheimer's disease, AstraZeneca, BACE, lilly, phase III

AstraZeneca and Eli Lilly have announced that the US Food and Drug Administration (FDA) has granted AZD3293 its fast track …

News
astrazeneca_building_white

Thousands to benefit with new anti-clotting drug recommendation, says NICE

August 12, 2016
Medical Communications, Sales and Marketing AstraZeneca, Brilique, ticagrelor

The National Institute for Health and Care Excellence (NICE) has published new draft guidance recommending AstraZeneca’s Brilique (ticagrelor) for people …

News
astrazeneca_building_white

AstraZeneca’s selumetinib fails to meet primary endpoint in lung cancer trial again

August 9, 2016
Manufacturing and Production AstraZeneca, failure, non-small cell lung cancer, phase III, selumetinib, trial failure

AstraZeneca has announced that its MEK 1/2 inhibitor, selumetinib, failed to meet its primary endpoint of progression free survival in …

News
astrazeneca_building_white

Cholesterol drugs drag AstraZeneca’s profits down in latest financial results

July 28, 2016
Research and Development, Sales and Marketing 2016, AstraZeneca, Q2, h1, results

AstraZeneca has maintained its financial outlook for 2016, despite its Q2 and H1 results showing sharp falls in core earnings …

News
cq5dam

New drugs to utilise DNA damage response to kill cancer cells

July 26, 2016
Research and Development, Sales and Marketing AstraZeneca, Cancer, Wellcome Trust, chemotherapy, dna damage response, university of sussex

The University of Sussex is set to produce a portfolio of new cancer drugs which exploit our DNA damage response …

News

AstraZeneca’s Zavicefta meets primary endpoint in Phase III pneumonia trials

July 21, 2016
Research and Development Antibiotics, AstraZeneca, zavifecta

AstraZeneca has announced results from a Phase III trial for its recently approved antibiotic, Zavicefta (ceftazidime-avibactam), which met its primary …

News
astrazeneca_crestor_rosuvastatin_40mg

AstraZeneca loses legal bid to block Crestor generics

July 20, 2016
Research and Development, Sales and Marketing AstraZeneca, Crestor, FDA, generics, legal

A US district court judge has refused AstraZeneca’s request for a temporary restraining order blocking the approval of generic versions …

News
astrazeneca-sign

AstraZeneca presents positive Phase III results for lung cancer drug Tagrisso

July 18, 2016
Manufacturing and Production, Research and Development AstraZeneca, Tagrisso

AstraZeneca has presented results from the latest Phase III trial evaluating Tagrisso (osimertinib) as a second line treatment for patients …

News
logo

AstraZeneca mulling a $10-billion bid for Medivation – report

July 12, 2016
Manufacturing and Production, Sales and Marketing AstraZeneca, Celgene, Medivation, Pfizer, Xtandi, cancer drug, merger and acquisition

Anglo Swedish drug firm AstraZeneca (LSE: AZN) is considering a $10-billion takeover bid for Medivation (Nasdaq: MDVN), according to reports. …

News
astrazeneca_sign_sky

AstraZeneca files suit to block FDA from approving copies of cholesterol drug Crestor

July 11, 2016
Sales and Marketing AstraZeneca, Crestor, US FDA, patent, regulation

Anglo-Swedish drug firm AstraZeneca (LSE: AZN) has filed a temporary restraining order to prevent the US Food and Drug Administration from …

News
az_logo

AstraZeneca trigger $10 million milestone payment for Heptares in immuno-oncology candidate

July 6, 2016
Research and Development, Sales and Marketing AstraZeneca, Heptares

AstraZeneca (LSE: AZN) is set to deliver a payment of $10 million to Heptares Therapeutics after the first patient was …

News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026